SynthesisAnnals of nuclear medicine2025
Diagnostic accuracy of 18F-FDG and 68 Ga-FAPi PET/CT for patients with gastric carcinoma: a systematic review and meta-analysis.
Synthesis in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis systematic review aims to assess the diagnostic performance of FDG PET/CT and FAPi PET/CT in patients with gastric carcinoma, specifically for the evaluation of primary tumors, metastatic lymph nodes, and metastatic lesions.
methodsFollowing PRISMA guidelines, relevant databases were searched until January 20, 2023. Studies reporting histopathology or surgical outcomes as the reference standard were included. Pooled estimates of diagnostic accuracy were generated using meta-analysis.
resultsSix studies with 167 patients who underwent FDG PET/CT and 169 patients who underwent FAPi PET/CT were included. For the detection of primary gastric carcinoma, FDG PET/CT demonstrated a pooled sensitivity of 0.86 (95% CI 0.47-0.98) and specificity of 0.70 (95% CI 0.39-0.90). The pooled positive likelihood ratio was 2.9 (95% CI 1.0-8.4), and the negative likelihood ratio was 0.21 (95% CI 0.03-1.30). The diagnostic odds ratio was 14 (95% CI 1-224), and the area under the SROC curve was 0.82. For FAPi PET/CT, pooled sensitivity and specificity for detecting primary gastric carcinoma were 0.90 (95% CI 0.90-0.90) and 0.50 (95% CI 0.50-0.50), respectively. The pooled positive and negative likelihood ratios were 1.8 (95% CI 1.8-1.8) and 0.20 (95% CI 0.20-0.20), respectively. The diagnostic odds ratio was 9 (95% CI 9-9), and the area under the SROC curve was 0.54.
conclusionFAPi PET/CT demonstrated comparable diagnostic performance to FDG PET/CT in the diagnosis of primary gastric carcinoma, lymph nodal metastases, and metastatic lesions. When compared to histopathology or surgical findings, FAPi PET/CT showed good sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio.
Indexed as
Identifiers
40643859What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.